Related Experiment Video

Updated: Jan 6, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

18.7K

Triple-Negative Breast Cancer: The Progress of Targeted Therapies and Future Tendencies

Christos Damaskos1, Anna Garmpi2, Konstantinos Nikolettos3

  • 1Second Department of Propedeutic Surgery, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece x_damaskos@yahoo.gr.

Anticancer Research
|October 2, 2019
PubMed

Insights

Triple-negative breast cancer (TNBC) lacks targeted therapies, necessitating new treatments. This review highlights promising clinical studies on targeted therapies like PARP-1 inhibitors and PI3K/AKT/mTOR pathway modulators for TNBC.

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Triple-negative breast cancer (TNBC) lacks targeted therapies due to negative ER, PR, and HER2 expression.
  • Chemotherapy remains the primary treatment, but resistance is a significant clinical challenge.
  • Developing novel therapeutic strategies is crucial for improving TNBC patient outcomes.

Purpose of the Study:

  • To review recent clinical studies (last five years) identifying potential targeted therapies for TNBC.
  • To discuss emerging therapeutic targets and pathways relevant to TNBC treatment.

Main Methods:

  • Descriptive summary of data from 18 clinical trials involving TNBC patients.
  • Literature review focusing on clinical studies published within the last five years.

Main Results:

  • Identified several promising targeted therapy approaches for TNBC.
  • Highlighted tyrosine kinase inhibitors, anti-androgens, PARP-1 inhibitors, anti-angiogenic factors, immune checkpoints, and HDACIs as potential treatments.
  • The PI3K/AKT/mTOR pathway emerged as a key area for developing new anti-TNBC therapies.

Conclusions:

  • Recent clinical trials suggest several targeted therapies show promise for TNBC.
  • The PI3K/AKT/mTOR pathway represents a significant avenue for future TNBC drug development.
  • Further research and clinical trials are essential to validate these targeted approaches for TNBC treatment.
Keywords:
Triple-negativebreast cancerreviewtargetedtherapies

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.6K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K